価格表

在庫・価格 : 2025年05月02日 22時38分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-HdmX/MDM4, Rabbit-Poly, AbVantage Pack
データシート※最新のデータシートでない場合があります
A310-107A BETベチル ラボラトリーズ
Bethyl Laboratories, Inc.
1 pack 本製品は取扱中止になりました 追加

在庫・価格 : 2025年05月02日 22時38分 現在

Anti-HdmX/MDM4, Rabbit-Poly, AbVantage Pack

  • 商品コード:A310-107A
  • メーカー:BET
  • 包装:1pack
  • 本製品は取扱中止になりました
使用文献
No. 文献情報 備考 参照
1 Bozzi F et al. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. Lab. Invest. 2013 Nov;93(11):1232-40
Bozzi F et al
2013/01/01
PubMed
2 Patton JT et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006 Mar;66(6):3169-76
Patton JT et al
2006/01/01
PubMed
3 Wade M et al. Hdmx modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 2006 Nov;281(44):33036-44
Wade M et al
2006/01/01
PubMed
4 Smalley KS et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 2007 Jan;67(1):209-17
Smalley KS et al
2007/01/01
PubMed
5 Kawai H et al. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res. 2007 Jul;67(13):6026-30
Kawai H et al
2007/01/01
PubMed
6 Wang YV et al. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc. Natl. Acad. Sci. U.S.A. 2007 Jul;104(30):12365-70
Wang YV et al
2007/01/01
PubMed
7 Lopez-Pajares V et al. Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding. J. Biol. Chem. 2008 May;283(20):13707-13
Lopez-Pajares V et al
2008/01/01
PubMed
8 Veerakumarasivam A et al. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clin. Cancer Res. 2008 May;14(9):2527-34
Veerakumarasivam A et al
2008/01/01
PubMed
9 Markey M et al. Full-length hdmX transcripts decrease following genotoxic stress. Oncogene 2008 Nov;27(52):6657-66
Markey M et al
2008/01/01
PubMed
10 Forte E et al. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J. Virol. 2009 Mar;83(6):2491-9
Forte E et al
2009/01/01
PubMed
11 Huang B et al. Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol. Cancer Res. 2009 Sep;7(9):1497-509
Huang B et al
2009/01/01
PubMed
12 Jobson AG et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J. Pharmacol. Exp.
Jobson AG et al
2009/01/01
PubMed
13 Chen W et al. Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas. J. Virol. 2010 Apr;84(8):3898-908
Chen W et al
2010/01/01
PubMed
14 Long J et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 2010 Jul;116(1):71-80
Long J et al
2010/01/01
PubMed
15 Thompson T et al. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Mol. Cancer Ther. 2010 May;9(5):1158-68
Thompson T et al
2010/01/01
PubMed
16 Jin G et al. HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro-oncology 2010 Sep;12(9):956-66
Jin G et al
2010/01/01
PubMed
17 Nie J et al. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2. J. Biol. Chem. 2010 Jul;285(30):22818-30
Nie J et al
2010/01/01
PubMed
18 Kojima K et al. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol. Cancer Ther. 2010 Sep;9(9):2545-57
Kojima K et al
2010/01/01
PubMed
19 Marcar L et al. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res. 2010 Dec;70(24):10362-70
Marcar L et al
2010/01/01
PubMed
20 Wang H et al. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol. Cancer Ther. 2011 Jan;10(1):69-79
Wang H et al
2011/01/01
PubMed
21 Waning DL et al. c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation. J. Biol. Chem. 2011 Jan;286(1):216-22
Waning DL et al
2011/01/01
PubMed
22 Wynendaele J et al. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res. 2010 Dec;70(23):9641-9
Wynendaele J et al
2010/01/01
PubMed
23 Pishas KI et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin. Cancer Res. 2011 Feb;17(3):494-504
Pishas KI et al
2011/01/01
PubMed
24 Lee JH et al. 14-3-3Gamma inhibition of MDMX-mediated p21 turnover independent of p53. J. Biol. Chem. 2011 Feb;286(7):5136-42
Lee JH et al
2011/01/01
PubMed
25 Anderson VE et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011 Jan;71(2):463-72
Anderson VE et al
2011/01/01
PubMed
26 Li D et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 2011 May;9(5):577-88
Li D et al
2011/01/01
PubMed
27 Wang X et al. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J. Biol. Chem. 2011 Jul;286(27):23725-34
Wang X et al
2011/01/01
PubMed
28 Biderman L et al. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress. Mol. Cell. Biol. 2012 Apr;32(7):1214-25
Biderman L et al
2012/01/01
PubMed
29 Lee JH et al. Hypoxia activates tumor suppressor p53 by inducing ATR-Chk1 kinase cascade-mediated phosphorylation and consequent 14-3-3γ inactivation of MDMX protein. J. Biol. Chem. 2012 Jun;287(25):20898-903
Lee JH et al
2012/01/01
PubMed
30 Henze J et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS ONE 2012;7(5):e37776
Henze J et al
2012/01/01
PubMed
31 Leventaki V et al. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. Br. J. Haematol. 2012 Sep;158(6):763-71
Leventaki V et al
2012/01/01
PubMed
32 Mandke P et al. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS ONE 2012;7(8):e42034
Mandke P et al
2012/01/01
PubMed
33 McEvoy J et al. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS ONE 2012;7(8):e42739
McEvoy J et al
2012/01/01
PubMed
34 Lu Z et al. Protein phosphatase 1 inhibits p53 signaling by dephosphorylating and stabilizing Mdmx. Cell. Signal. 2013 Apr;25(4):796-804
Lu Z et al
2013/01/01
PubMed
35 Wong VC et al. p53 activation by Ni(II) is a HIF-1α independent response causing caspases 9/3-mediated apoptosis in human lung cells. Toxicol. Appl. Pharmacol. 2013 Apr;269(3):233-239
Wong VC et al
2013/01/01
PubMed
36 Ranaweera RS et al. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity. J. Biol. Chem. 2013 Jun;288(26):18939-46
Ranaweera RS et al
2013/01/01
PubMed
37 Donati G et al. 5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Rep 2013 Jul;4(1):87-98
Donati G et al
2013/01/01
PubMed
38 Daftuar L et al. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS ONE 2013;8(7):e68667
Daftuar L et al
2013/01/01
PubMed
39 Chang YS et al. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 2013 Sep;110(36):E3445-54
Chang YS et al
2013/01/01
PubMed
40 Green SE et al. Uptake, p53 pathway activation, and cytotoxic responses for Co(II) and Ni(II) in human lung cells: implications for carcinogenicity. Toxicol. Sci. 2013 Dec;136(2):467-77
Green SE et al
2013/01/01
PubMed
41 Le達o M et al. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity. FEBS J. 2013 Dec;280(24):6498-507
Le達o M et al
2013/01/01
PubMed
42 Qi M et al. DNAJB1 stabilizes MDM2 and contributes to cancer cell proliferation in a p53-dependent manner. Biochim. Biophys. Acta 2014 Jan;1839(1):62-9
Qi M et al
2014/01/01
PubMed
43 van der Ent W et al. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. J. Pathol. 2014 Aug;233(4):415-24
van der Ent W et al
2014/01/01
PubMed
44 Roh JL et al. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer. Apoptosis 2014 Nov;19(11):1594-602
Roh JL et al
2014/01/01
PubMed
45 Le達o M et al. Studying p53 family proteins in yeast: Induction of autophagic cell death and modulation by interactors and small molecules. Exp. Cell Res. 2015 Jan;330(1):164-77
Le達o M et al
2015/01/01
PubMed
46 Zaytsev A et al. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach. Chem Biol Drug Des 2015 Aug;86(2):180-9
Zaytsev A et al
2015/01/01
PubMed
47 Ling X et al. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX. Cancer Res. 2014 Dec;74(24):7487-97
Ling X et al
2014/01/01
PubMed
48 Pereg Y et al. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 2005 Apr;102(14):5056-61
Pereg Y et al
2005/01/01
PubMed
49 Burmakin M et al. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin. Cancer Res. 2013 Sep;19(18):5092-103
Burmakin M et al
2013/01/01
PubMed
  • No.: 1
  • 文献情報:
    Bozzi F et al. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. Lab. Invest. 2013 Nov;93(11):1232-40
    Bozzi F et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Patton JT et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006 Mar;66(6):3169-76
    Patton JT et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Wade M et al. Hdmx modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 2006 Nov;281(44):33036-44
    Wade M et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Smalley KS et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 2007 Jan;67(1):209-17
    Smalley KS et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Kawai H et al. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res. 2007 Jul;67(13):6026-30
    Kawai H et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Wang YV et al. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc. Natl. Acad. Sci. U.S.A. 2007 Jul;104(30):12365-70
    Wang YV et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Lopez-Pajares V et al. Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding. J. Biol. Chem. 2008 May;283(20):13707-13
    Lopez-Pajares V et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Veerakumarasivam A et al. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clin. Cancer Res. 2008 May;14(9):2527-34
    Veerakumarasivam A et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Markey M et al. Full-length hdmX transcripts decrease following genotoxic stress. Oncogene 2008 Nov;27(52):6657-66
    Markey M et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Forte E et al. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J. Virol. 2009 Mar;83(6):2491-9
    Forte E et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Huang B et al. Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol. Cancer Res. 2009 Sep;7(9):1497-509
    Huang B et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Jobson AG et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J. Pharmacol. Exp.
    Jobson AG et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Chen W et al. Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas. J. Virol. 2010 Apr;84(8):3898-908
    Chen W et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Long J et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 2010 Jul;116(1):71-80
    Long J et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Thompson T et al. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Mol. Cancer Ther. 2010 May;9(5):1158-68
    Thompson T et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Jin G et al. HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro-oncology 2010 Sep;12(9):956-66
    Jin G et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Nie J et al. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2. J. Biol. Chem. 2010 Jul;285(30):22818-30
    Nie J et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Kojima K et al. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol. Cancer Ther. 2010 Sep;9(9):2545-57
    Kojima K et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Marcar L et al. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res. 2010 Dec;70(24):10362-70
    Marcar L et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Wang H et al. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol. Cancer Ther. 2011 Jan;10(1):69-79
    Wang H et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Waning DL et al. c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation. J. Biol. Chem. 2011 Jan;286(1):216-22
    Waning DL et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Wynendaele J et al. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res. 2010 Dec;70(23):9641-9
    Wynendaele J et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Pishas KI et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin. Cancer Res. 2011 Feb;17(3):494-504
    Pishas KI et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Lee JH et al. 14-3-3Gamma inhibition of MDMX-mediated p21 turnover independent of p53. J. Biol. Chem. 2011 Feb;286(7):5136-42
    Lee JH et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Anderson VE et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011 Jan;71(2):463-72
    Anderson VE et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Li D et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 2011 May;9(5):577-88
    Li D et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Wang X et al. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J. Biol. Chem. 2011 Jul;286(27):23725-34
    Wang X et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Biderman L et al. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress. Mol. Cell. Biol. 2012 Apr;32(7):1214-25
    Biderman L et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Lee JH et al. Hypoxia activates tumor suppressor p53 by inducing ATR-Chk1 kinase cascade-mediated phosphorylation and consequent 14-3-3γ inactivation of MDMX protein. J. Biol. Chem. 2012 Jun;287(25):20898-903
    Lee JH et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Henze J et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS ONE 2012;7(5):e37776
    Henze J et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Leventaki V et al. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. Br. J. Haematol. 2012 Sep;158(6):763-71
    Leventaki V et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Mandke P et al. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS ONE 2012;7(8):e42034
    Mandke P et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    McEvoy J et al. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS ONE 2012;7(8):e42739
    McEvoy J et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 34
  • 文献情報:
    Lu Z et al. Protein phosphatase 1 inhibits p53 signaling by dephosphorylating and stabilizing Mdmx. Cell. Signal. 2013 Apr;25(4):796-804
    Lu Z et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 35
  • 文献情報:
    Wong VC et al. p53 activation by Ni(II) is a HIF-1α independent response causing caspases 9/3-mediated apoptosis in human lung cells. Toxicol. Appl. Pharmacol. 2013 Apr;269(3):233-239
    Wong VC et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 36
  • 文献情報:
    Ranaweera RS et al. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity. J. Biol. Chem. 2013 Jun;288(26):18939-46
    Ranaweera RS et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 37
  • 文献情報:
    Donati G et al. 5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Rep 2013 Jul;4(1):87-98
    Donati G et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 38
  • 文献情報:
    Daftuar L et al. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS ONE 2013;8(7):e68667
    Daftuar L et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 39
  • 文献情報:
    Chang YS et al. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 2013 Sep;110(36):E3445-54
    Chang YS et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 40
  • 文献情報:
    Green SE et al. Uptake, p53 pathway activation, and cytotoxic responses for Co(II) and Ni(II) in human lung cells: implications for carcinogenicity. Toxicol. Sci. 2013 Dec;136(2):467-77
    Green SE et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 41
  • 文献情報:
    Le達o M et al. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity. FEBS J. 2013 Dec;280(24):6498-507
    Le達o M et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 42
  • 文献情報:
    Qi M et al. DNAJB1 stabilizes MDM2 and contributes to cancer cell proliferation in a p53-dependent manner. Biochim. Biophys. Acta 2014 Jan;1839(1):62-9
    Qi M et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 43
  • 文献情報:
    van der Ent W et al. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. J. Pathol. 2014 Aug;233(4):415-24
    van der Ent W et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 44
  • 文献情報:
    Roh JL et al. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer. Apoptosis 2014 Nov;19(11):1594-602
    Roh JL et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 45
  • 文献情報:
    Le達o M et al. Studying p53 family proteins in yeast: Induction of autophagic cell death and modulation by interactors and small molecules. Exp. Cell Res. 2015 Jan;330(1):164-77
    Le達o M et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 46
  • 文献情報:
    Zaytsev A et al. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach. Chem Biol Drug Des 2015 Aug;86(2):180-9
    Zaytsev A et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 47
  • 文献情報:
    Ling X et al. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX. Cancer Res. 2014 Dec;74(24):7487-97
    Ling X et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 48
  • 文献情報:
    Pereg Y et al. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 2005 Apr;102(14):5056-61
    Pereg Y et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 49
  • 文献情報:
    Burmakin M et al. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin. Cancer Res. 2013 Sep;19(18):5092-103
    Burmakin M et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed